Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Two month old infant (50 to 71 days old) on the day of inclusion, of either gender.~* Born at full term of pregnancy (\>= 37 weeks) and with a birth weight \>= 2.5 kg.~* Hepatitis B vaccination since birth.~* Informed consent form signed by one parent/legally acceptable representative and an independent witness if the parent/legally acceptable representative is illiterate.~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria :~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances.~* Congenital or acquired immunodeficiency, or immunosuppressive therapy such as long-term systemic corticosteroid therapy.~* Chronic illness at a stage that could interfere with trial conduct or completion.~* Blood or blood-derived products received since birth.~* Any vaccination in the 4 weeks preceding the first trial vaccination.~* Any planned vaccination (except trial vaccinations) during the trial.~* Documented history of pertussis, T, D, polio, Hib, hepatitis B or Streptococcus pneumoniae infection(s) (confirmed either clinically, serologically, or microbiologically).~* Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b infection(s) or Streptococcus pneumoniae.~* Known personal or maternal history of HIV, HB (HbsAg carrier) or hepatitis C seropositivity.~* Known thrombocytopenia or bleeding disorder contraindicating IM vaccination.~* History of seizures.~* Febrile (rectal equivalent temperature \>= 38.0°C) or acute illness on the day of inclusion.

- Gender: ALL
- Minimum Age: 50 Days
- Maximum Age: 71 Days
- Healthy Volunteers: t

Study Arms:
- Group 1: DTaP IPV Hep B PRP T + Prevnar™ (Type: EXPERIMENTAL): None
- Group 2: Infanrix hexa™ + Prevnar™ (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).